Urologie (Heidelberg, Germany)
[Poly (ADP-ribose) polymerase inhibitor combination therapy in metastatic castration-resistant prostate cancer].
Carsten Ohlmann, Christian Gratzke, Laura-Maria Krabbe
Published: 202510.1007/s00120-025-02747-7
Abstract
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge. Poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) combined with new hormonal agents (NHA) offer novel treatment options. OBJECTIVE: Th…
Preview only. Read the full abstract at the source